Detecting IDH1 Mutations in Gliomas: Insights from J-Difference Editing MEGA-PRESS 1H-MRS

Motivation: Detecting isocitrate dehydrogenase 1 (IDH1) mutations via in vivo MRI can significantly aids glioma diagnosis and treatment strategies. Goal(s): To investigates the use of MEGA-PRESS sequences to non-invasively charaterize the metabolic profile of IDH1 mutation glioma. Approach: We measured 2-hydroxyglutarate (2HG), glutamate+glutamine (GLX), GABA and glutathione (GSH) inside the glioma from an IDH1(R132H)-mutant and an IDH1-wildtype murine models. Results: The results unveil distinctive metabolic changes in IDH1 mutation tumors, including elevated 2HG, GLX/GABA ratio, and reduced GSH. These findings offer potential biomarkers for precise diagnosis and therapeutic strategies, highlighting the significant role of MEGA-PRESS in the studies of glioma. Impact: The study identifies 1H MRS-based biomarkers for non-invasive detection of IDH1 mutation tumors using the MEGA-PRESS sequence. It provides insights into metabolic changes and neurochemical imbalances, aiding early diagnosis, treatment guidance, and monitoring, thus advancing precision oncology.